Substrate specificity and antinuclear antibodies in scleroderma

14Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Studies of antinuclear antibodies (ANA) were carried out in 39 cases of systemic scleroderma (progressive systemic sclerosis) and for comparison in 19 cases of systemic lupus erythematosus (SLE) and 4 of mixed connective tissue disease (MCTD) using indirect immunofluorescence (IF) methods under standard conditions. The results on 3 different substrates - monkey esophagus, guinea-pig lip and rat liver - are reported. In 48.7% of scleroderma cases ANA showed a substrate specificity. The highest percentage of positive results in scleroderma was obtained on monkey esophagus (97.4%) and the lowest on rat liver (61.5%). In SLE and MCTD, in contrast, only about 13% of the sera displayed such specificity. If only sera with substrate specificity are considered, the positive results on monkey esophagus and rat liver are 94.7% and 21.1%, respectively. Titers of sera reacting positively on 2 or 3 substrates were mostly in agreement, although some sera both in systemic scleroderma and SLE showed higher titers on monkey esophagus. The IF pattern was usually the same regardless of the substrate. Tests for ANA in scleroderma should be performed on at least 2 substrates simultaneously.

Cite

CITATION STYLE

APA

Blaszczyk, M., Beutner, E. H., & Rogozinski, T. (1977). Substrate specificity and antinuclear antibodies in scleroderma. Journal of Investigative Dermatology, 68(4), 191–193. https://doi.org/10.1111/1523-1747.ep12492668

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free